COGT News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

CO

Mkt Cap

$5.12B

Volume

2.34M

Next Earnings

November 6th

Loading chart

CO

COGTCogent Biosciences, Inc. Common Stock

COGT

Pay with—

Available Balance0.00

CO

Mkt Cap

$5.12B

Volume

2.34M

Next Earnings

November 6th

Chart Financials Earnings News About Insider Filings

Cogent Biosciences Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026Cogent Biosciences announced preclinical data presentations at the 2026 AACR Annual Meeting for two pipeline programs: CGT1263, a pan-KRAS(ON) inhibitor showing >500x selectivity over HRAS/NRAS with potential to reduce skin toxicity, and CGT4255, a brain-penetrant ErbB2 inhibitor demonstrating synergistic activity with HER2 ADCs. The company expects to submit an IND for CGT1263 later in 2026 and continues Phase 1 studies for CGT4255.GlobeNewswire Inc. · Apr 17, 2026

This $116 Million Buy Joins a 360% Stock Run and Seemingly Signals Conviction in a Key Drug LaunchRTW Investments made a significant $116 million purchase of Cogent Biosciences shares in Q4, increasing its stake to 2.7% of AUM. The move signals confidence in the biotech company's lead drug candidate (CGT9486) and upcoming FDA decision timeline in late 2026. Cogent's stock has surged 360% over the past year, and the company has $900 million in cash runway through 2028.The Motley Fool · Mar 21, 2026

Biotech Stock Up 372% Gets Sold as New Pick Rises 40% in 2026Boone Capital Management liquidated its entire $13.57 million stake in Cogent Biosciences (945,042 shares) in Q4 2026, despite the stock surging 372% over the past year. The fund reallocated capital to earlier-stage biotech opportunities like TYRA, which has gained 40% in 2026, suggesting a strategic shift toward higher-risk, higher-upside clinical-stage investments.The Motley Fool · Mar 20, 2026

Cogent Biosciences Stock Climbs After FDA Accepts Key Drug ApplicationCogent Biosciences stock surged 5.24% after the FDA accepted its New Drug Application for bezuclastinib, a treatment for Non-Advanced Systemic Mastocytosis. The FDA decision is expected by December 30, 2026, with no advisory committee meeting planned. The company also plans to submit additional NDAs for GIST and Advanced Systemic Mastocytosis treatments in 2026.Benzinga · Mar 16, 2026

Cogent Biosciences Highlights Additional Data with Six Bezuclastinib Posters from SUMMIT Trial at 2026 AAAAI Annual MeetingCogent Biosciences announced additional clinical results from the SUMMIT trial showing bezuclastinib achieved a mean TSS reduction of -32.0 points at 48 weeks, with 99% of patients achieving >50% reduction in serum tryptase and 83% achieving normalization. The data demonstrates consistent symptomatic improvements across multiple organ systems and evidence of disease modification in NonAdvanced Systemic Mastocytosis patients. The company's NDA for bezuclastinib in NonAdvSM was submitted in December 2025, with an APEX NDA submission for advanced SM expected in 1H 2026.GlobeNewswire Inc. · Feb 28, 2026

Cogent Biosciences Announces Multiple SUMMIT Posters at the 2026 AAAAI Annual MeetingCogent Biosciences announced multiple poster presentations highlighting bezuclastinib results from the SUMMIT trial in NonAdvanced Systemic Mastocytosis patients at the 2026 AAAAI Annual Meeting in Philadelphia. The company previously submitted a New Drug Application to the FDA in December 2025 based on positive clinical data, following the drug's Breakthrough Therapy Designation.GlobeNewswire Inc. · Feb 10, 2026

Cogent's New Stomach Cancer Treatment Cuts Progression Risk In Half, Gets Breakthrough Therapy TagThe FDA granted Breakthrough Therapy Designation to Cogent Biosciences' bezuclastinib combined with sunitinib for gastrointestinal stromal tumors (GIST). The PEAK trial showed a 50% reduction in disease progression risk compared to sunitinib alone, with median PFS of 16.5 months versus 9.2 months. The combination was well-tolerated with no new safety concerns. Cogent expects to complete its NDA submission in April 2026 and initiate a Phase 2 trial for first-line GIST patients in mid-2026.Benzinga · Jan 26, 2026

Cogent Biosciences Announces Presentation at the 44th Annual J.P. Morgan Healthcare ConferenceCogent Biosciences announced that CEO Andrew Robbins will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026. The company is developing precision therapies for genetically defined diseases, with bezuclastinib as its most advanced program for systemic mastocytosis and gastrointestinal stromal tumors. Recent positive trial results showed a 57-80% objective response rate in advanced systemic mastocytosis patients.GlobeNewswire Inc. · Jan 6, 2026

Cogent Biosciences Presents Full SUMMIT Results of Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 67th Annual Meeting of the American Society of Hematology (ASH)Cogent Biosciences announced positive clinical trial results for bezuclastinib, demonstrating significant improvements in symptoms and disease markers for patients with nonadvanced systemic mastocytosis, with plans to submit a New Drug Application in December 2025.GlobeNewswire Inc. · Dec 6, 2025

Cogent Biosciences Announces Participation in the Jefferies Global Healthcare ConferenceCogent Biosciences will participate in the Jefferies Global Healthcare Conference in London, presenting a live webcast about their precision therapies for genetically defined diseases, with a focus on their lead clinical program bezuclastinib.GlobeNewswire Inc. · Nov 14, 2025

to start trading

CO

COGTCogent Biosciences, Inc. Common Stock

COGT

Pay with—

Available Balance0.00

Your PositionYou don't own any COGT yet.

Related Tickers

Earnings